News

AOD-9604 au Québec en 2026 : où en est la vente...

July 8, 2026

En 2026, la vente en ligne d'AOD-9604 au Québec subit des restrictions majeures. Cet article fait le point sur les interventions de Santé Canada, les

AOD-9604 au Québec en 2026 : où en est la vente...

July 8, 2026

En 2026, la vente en ligne d'AOD-9604 au Québec subit des restrictions majeures. Cet article fait le point sur les interventions de Santé Canada, les

AOD-9604 and GLP-1 Agonists: Regulatory Pathway...

June 25, 2026

AOD-9604 remains unapproved while GLP-1 agonists hold FDA authorization for weight loss. Bone health signals differ between compounds, with GLP-1 data showing BMD loss and AOD-9604 lacking human skeletal studies.

AOD-9604 and GLP-1 Agonists: Regulatory Pathway...

June 25, 2026

AOD-9604 remains unapproved while GLP-1 agonists hold FDA authorization for weight loss. Bone health signals differ between compounds, with GLP-1 data showing BMD loss and AOD-9604 lacking human skeletal studies.

Beauport Peptides (PC)

High-quality peptides designed for consistency, purity, and trusted research performance.

QUICK LINKS

OUR POLICIES

CONTACT

info@beauportpeptides.ca

330 Lacewood Dr, Halifax, NS B3S 0A3, Canada

⚠ Research Use Only — Legal Disclaimer

All compounds on this website are sold as raw research materials for laboratory use only. They are not therapeutic, diagnostic, or consumer products and are not approved by any health authority for use in humans or animals. Purchasers acknowledge their professional qualifications and accept sole responsibility for compliant, lawful, and safe use of all purchased compounds. We expressly disclaim any and all liability for harm, misuse, or regulatory violation.

© 2026 Beauport Peptides (PC). All rights reserved.